CLINICAL TRIALS

Mesoblast sows the seeds for stem cell success

roymorgansocial Leave a comment

Original article by Rick Wallace
The Australian – Page: 15 & 16 : 28-Jul-14

A new regulatory environment in Japan means it will be the initial market in which Australian-listed biotechnology group Mesoblast launches its revolutionary stem cells therapy product. CEO Silviu Itescu notes that this will be a world first, and should boost stock analysts’ forecasts for the company. A 2016 launch in the US is also being aimed for. In that nation Mesoblast has concluded phase III clinical trials of mesenchymal stem cells for treating childhood graft-versus-host-disease. The group has cash holdings of about $A220m, and can allocate funding to separate trials of its degenerative disc repair product

CORPORATES
MESOBLAST LIMITED – ASX MSB, UNITED STATES. FOOD AND DRUG ADMINISTRATION, JCR PHARMACEUTICALS COMPANY LIMITED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, GOLDMAN SACHS AUSTRALIA PTY LTD, BELL POTTER SECURITIES LIMITED, BELL FINANCIAL GROUP LIMITED – ASX BFG

New drug regimen gives hope to millions

roymorgansocial Leave a comment

Original article by Julia Medew
The Sydney Morning Herald – Page: 7 : 22-Jul-14

A new treatment called PaMZ has been shown to fight tuberculosis (TB) while still allowing anti-retroviral drugs to be used that target the human immunodeficiency virus (HIV). The 20th international congress on the Acquired Immunodeficiency Syndrome (AIDS) in Melbourne on 21 July 2014 heard from Global TB Alliance senior medical officer Daniel Everitt on the promising clinical trials. TB accounts for about 20% of all deaths among those suffering from HIV or AIDS. PaMZ may be widely available from 2018

CORPORATES
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT